How does 5-Amino-1MQ differ from GLP-1 drugs for weight loss?

Completely different mechanism. GLP-1 drugs reduce appetite — you eat less. 5-Amino-1MQ doesn't affect food intake at all. Instead, it increases cellular energy expenditure by preserving NAD+ levels, essentially making fat cells burn more energy. In mouse studies, treated animals ate the same amount but lost significantly more weight. This makes it a potential complement to GLP-1 therapy, not a competitor.

How does 5-Amino-1MQ relate to NAD+ supplements like NMN?

They're two sides of the same coin. NMN/NR provide raw material to make more NAD+. 5-Amino-1MQ blocks the enzyme (NNMT) that drains NAD+ away. Combining both — increasing NAD+ production while blocking its degradation — is theoretically synergistic, though this hasn't been tested in clinical trials.

Is 5-Amino-1MQ available?

It's available through some compounding pharmacies and research peptide vendors with a prescription. It is not FDA-approved for any indication. No human clinical trials have been completed. Quality varies significantly across sources.

5-Amino-1MQ

A selective NNMT inhibitor that reduces fat mass by boosting NAD+ and cellular energy expenditure — without affecting appetite. In mice, 11 days of treatment produced 5% weight loss and 35% reduction in white adipose tissue.

PreliminaryLimited Data

What is 5-Amino-1MQ?

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that drains the body's NAD+ supply by methylating nicotinamide. NNMT is overexpressed in white adipose tissue of obese individuals, creating a metabolic bottleneck that promotes fat storage. By blocking NNMT, 5-Amino-1MQ preserves cellular NAD+ levels, increases energy expenditure, and shifts metabolism away from fat storage — all without reducing food intake. In diet-induced obese mice, 11 days of treatment produced 5.1% body weight loss and a 35% reduction in white adipose tissue mass with over 40% smaller adipocytes. It is technically not a peptide but a quinolinium derivative, widely discussed in the peptide and metabolic optimization community. The foundational NNMT-obesity connection was published in Nature (2014).

Why People Talk About It

Fat loss without appetite suppression (different from GLP-1s)

Preliminary

NAD+ preservation and cellular energy metabolism

Preliminary

Reduced cholesterol (30% decrease in mice)

Preliminary

Potential synergy with NAD+ precursors (NMN/NR)

Limited

How It Works

Your body has an enzyme called NNMT that breaks down a molecule needed for cellular energy (NAD+). In obese people, NNMT is overactive in fat tissue, draining NAD+ and slowing metabolism. 5-Amino-1MQ blocks this enzyme, preserving NAD+ levels. With more NAD+ available, fat cells burn more energy — leading to fat loss without needing to eat less.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

No human safety data — preclinical onlyNo adverse effects reported in published mouse studies at therapeutic dosesFood intake was not affected (no appetite-related side effects)

Cautions

• No human clinical trials have been conducted
• Not FDA-approved
• NNMT plays roles beyond fat metabolism (epigenetics, cancer biology) — chronic inhibition effects unknown
• Highly selective for NNMT (does not inhibit related SAM-dependent methyltransferases), which is favorable for safety

What We Don't Know

Human pharmacokinetics, dosing, and safety are entirely unknown. NNMT has roles in cancer biology (both tumor-promoting and tumor-suppressing depending on context) — whether long-term NNMT inhibition has oncological implications is unstudied. The 11-day mouse study is too short to assess chronic safety.

Published Research

5 studies

Exploring NNMT: from metabolic pathways to therapeutic targets.

ReviewPMID: 39604638

Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.

PreclinicalPMID: 24717514

Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.

Preclinical

Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.

Preclinical

Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes.

Review

Mechanism of Action

5-Amino-1MQ is a selective, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA) and consuming both SAM and NAD+ precursors. In white adipose tissue, NNMT overexpression in obesity creates a metabolic drain: reduced NAD+ impairs oxidative metabolism, and reduced SAM impairs polyamine flux, both favoring fat storage. 5-Amino-1MQ inhibition reverses this: it increases intracellular NAD+ and SAM, upregulates polyamine metabolism enzymes (ODC, SSAT, PAO), increases GLUT4 transporter expression, and enhances oxygen consumption in adipocytes. In diet-induced obese mice (11 days, 20 mg/kg x3/day SC), it produced 5.1% weight loss (vs 1.4% gain in controls), 35% reduction in epididymal white adipose tissue mass, >40% reduction in adipocyte volume, and 30% lower total cholesterol — all without altering food intake. The compound shows high selectivity, not inhibiting related SAM-dependent methyltransferases or NAD+ salvage pathway enzymes.

Evidence Snapshot

Overall Confidence35%

Human Clinical Evidence

None. No human clinical trials have been published for 5-Amino-1MQ. The compound is used off-label through compounding pharmacies but without clinical trial support.

Animal / Preclinical

Moderate. The key study demonstrated 5.1% weight loss, 35% WAT reduction, and 30% lower cholesterol in 11 days in DIO mice without altering food intake. The foundational Nature paper (2014) established NNMT knockdown as protective against diet-induced obesity via increased energy expenditure. Additional studies show reduced calorie diet combined with NNMT inhibition establishes a distinct beneficial microbiome.

Mechanistic Rationale

Strong. NNMT's role in obesity is well-validated (Nature, 2014). The NAD+/SAM/polyamine mechanistic cascade is well-characterized. 5-Amino-1MQ's selectivity for NNMT over related enzymes is confirmed. The absence of appetite effects (pure metabolic mechanism) is consistently demonstrated.

Forms & Administration

5-Amino-1MQ is available as an oral capsule through some compounding pharmacies, typically at 50-150 mg daily. In mouse studies, it was administered via subcutaneous injection at 20 mg/kg three times daily. Optimal human dosing is not established. All medications should only be used under the guidance of a qualified healthcare provider.

Use Cases & Evidence Levels

Fat loss without appetite suppression (different from GLP-1s)

Preliminary30%

NAD+ preservation and cellular energy metabolism

Preliminary30%

Reduced cholesterol (30% decrease in mice)

Preliminary30%

Potential synergy with NAD+ precursors (NMN/NR)

Limited15%

Safety Profile

Safety Information

Common Side Effects

No human safety data — preclinical onlyNo adverse effects reported in published mouse studies at therapeutic dosesFood intake was not affected (no appetite-related side effects)

Cautions

• No human clinical trials have been conducted
• Not FDA-approved
• NNMT plays roles beyond fat metabolism (epigenetics, cancer biology) — chronic inhibition effects unknown
• Highly selective for NNMT (does not inhibit related SAM-dependent methyltransferases), which is favorable for safety

What We Don't Know

Published Research

5 studies

Exploring NNMT: from metabolic pathways to therapeutic targets.

ReviewPMID: 39604638

Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.

PreclinicalPMID: 24717514

Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.

Preclinical

Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.

Preclinical

Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes.

Review

Related Peptides

NAD+ Precursors (NMN/NR)

ModerateBeginner

Precursors to NAD+, a critical coenzyme for cellular energy and longevity pathways. NAD+ levels decline with age.

MOTS-c

Emerging

A mitochondria-derived peptide that regulates metabolic homeostasis and has been called an 'exercise mimetic.'

AOD-9604

EmergingBeginner

A modified fragment of human growth hormone studied specifically for fat metabolism without the growth-promoting effects of full GH.

Semaglutide

StrongBeginner

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.

Tesofensine

Moderate

A triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) that produced up to 10.6% weight loss in Phase 2 trials — roughly double the efficacy of older appetite suppressants. Approved in Mexico; not yet FDA-approved.

Quick Facts

Class: Metabolic Modulator
Evidence: Preliminary
Safety: Limited Data
Updated: Apr 2026
Citations: 5PubMed

Also known as

5-Amino-1-MethylquinoliniumNNMT Inhibitor

Evidence Score

Overall Confidence35%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.